VJHemOnc is committed to improving our service to you

ESH AL 2018 | FLT3 inhibitors in the treatment of AML

VJHemOnc is committed to improving our service to you

Farhad Ravandi

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter